1065087--3/17/2008--ALBANY_MOLECULAR_RESEARCH

related topics

{acquisition, growth, future}

{product, liability, claim}

{product, candidate, development}

{operation, natural, condition}

{personnel, key, retain}

{stock, price, operating}

{customer, product, revenue}

{operation, international, foreign}

{system, service, information}

{property, intellectual, protect}

{stock, price, share}

{cost, regulation, environmental}

{tax, income, asset}

{regulation, government, change}

{cost, operation, labor}

{provision, law, control}

{product, market, service}

The introduction of a generic Allegra-D could materially impact royalty revenue. Pharmaceutical and biotechnology companies may discontinue or decrease their usage of our services. We may lose one or more of our major customers. We may be unsuccessful in producing and licensing proprietary technology developed from our internal research and development efforts or acquired from a third party. We may be unsuccessful in our collaboration with BMS. Our business may be adversely affected if we encounter complications in connection with our continued implementation and operation of information management software. Our goodwill may become impaired. Agreements we have with our employees, customers, consultants and other third parties may not afford adequate protection for our valuable intellectual property, confidential information and other proprietary information. Our failure to manage our expansion may adversely affect us. We may not be able to realize the benefits of recent acquisitions and strategic investments. Future acquisitions may disrupt our business and distract our management. We may not be able to effectively manage our international operations. We may not be able to recruit and retain the highly skilled employees we need. We may lose one or more of our key employees. We may be held liable for harm caused by drugs that we develop and test. We may be liable for contamination or other harm caused by hazardous materials that we use. If we fail to meet strict regulatory requirements, we could be required to pay fines or even close our facilities. Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities. Terrorist attacks or acts of war may seriously harm our business. Health care reform could reduce the prices pharmaceutical and biotechnology companies can charge for drugs they sell which, in turn, could reduce the amounts that they have available to retain our services. The ability of our stockholders to control our policies and effect a change of control of our company is limited, which may not be in your best interests. Our officers and directors have significant control over us and their interests may differ from yours. Because our stock price may be volatile, our stock price could experience substantial declines. Because we do not intend to pay dividends, you will benefit from an investment in our common stock only if it appreciates in value. We may experience disruptions in or the inability to source raw materials to support our production processes. We may experience significant increases in operational costs out of our control. We may be subject to foreign currency risks.

Full 10-K form ▸

1065087--3/17/2008--ALBANY_MOLECULAR_RESEARCH_INC